Start Date
January 31, 2017
Primary Completion Date
January 31, 2020
Pazopanib
A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
Trametinib
A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Collaborators (1)
Novartis
INDUSTRY
Sarcoma Alliance for Research through Collaboration
OTHER